Emalex Biosciences Stock

emalexbiosciences.comHealthcareFounded: 2018

Emalex Biosciences is a biopharma company that focuses on researching and developing drug treatments and therapies for central nervous system disorders. Emalex Biosciences uses experts in the clinical field that commit to a sustainable drug pipeline, clinical trial testing, and partnerships to fight and heal those afflicted with diseases of the nervous system.

Register for Details

For more details on financing and valuation for Emalex Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Emalex Biosciences.

Register Today

Team

Management Team

Jeff Aronin
Founder
Eric Messner
Chief Business Officer
Frederick Munschauer, M.D.
Chief Medical Officer
Atul R. Mahableshwarkar, M.D.
Chief Medical Officer

Other companies like Emalex Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM

News

Emalex Biosciences, a biotech startup, announced it raised $250 million in Series D funding led by Bain Capital.